RDIF和Samruk-Kazyna墨水合作备忘录以对抗COVID-19
发表于07/20/2020
俄罗斯直接投资基金和Samruk-Kazyna
已签署合作备忘录，以对抗冠状病毒COVID-19大流行。
哈萨克斯坦
现已收到9,500包阿维法韦，这是世界上第一个注册的基于favipiravir的抗冠状病毒药物。
根据新闻稿，
根据该备忘录，RDIF已向哈萨克斯坦共和国交付了第一批冠状病毒药物阿维法韦。
这是俄罗斯第一种被批准用于治疗冠状病毒感染的药物，也是世界上第一种注册的基于favipiravir的抗COVID-19药物，具有临床证明的功效。
Avifavir
blocks the reproduction mechanisms of coronavirus, relieving symptoms and halving the treatment period compared to standard therapy.
The efficacy has been proven in clinical trials held in 35 medical centers across Russia involving 330 patients with confirmed COVID-19.
RDIF and Samruk-Kazyna
have also agreed to cooperate in clinical trials, procurement and production of a vaccine against coronavirus.
In accordance with the memorandum,
the parties
will consider the possibility of obtaining the necessary certification in Kazakhstan for the first Russian vaccine against COVID-19 developed by the Gamaleya National Research Institute of Epidemiology and Microbiology to be supplied to the country or produced locally.
SWFI
Russian Direct Investment Fund :: RDIF and Samruk-Kazyna sign memorandum to cooperate in fight against coronavirus